By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion said today that its revenues rose to $431,000 in the first quarter, compared to $73,000 in Q1 2010, as more than 3,000 of its OVA1 ovarian cancer tests were performed.

The firm's results fell short of analysts' expectations of $520,000 in revenues.

For the three months ended March 31, product revenues came in at $317,000, compared to none a year ago, and licensing revenues were $114,000, up from $73,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.